About secukinum ab
Interleukin-17A inhibitor
Used for
- Plaque psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Hidradenitis suppurativa
Usual adult dose
Usually 150 mg or 300 mg under the skin at weeks 0, 1, 2, 3, and 4, then every 4 weeks; dose depends on condition.
Usual dose in children
For eligible children with plaque psoriasis: weight-based dose at weeks 0, 1, 2, 3, and 4, then every 4 weeks. Other pediatric uses vary.
Common side effects
- Upper respiratory infections
- Diarrhea
- Injection-site reactions
- Headache
Important warnings
- May increase risk of serious infections, including tuberculosis.
- Screen for tuberculosis before treatment; avoid live vaccines during treatment.
- May worsen inflammatory bowel disease or trigger new symptoms.
- Stop treatment and seek urgent care for severe allergic reactions.
Pregnancy
Human pregnancy data are limited; use only when clearly needed after discussion of risks and benefits.
Breastfeeding
Unknown whether secukinumab passes into breast milk; consider treatment benefits and potential infant risks.
Interactions
- Live vaccines may cause infection and should generally be avoided.
- Other biologic medicines that suppress immunity may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.